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ABSTRACT
Ames dwarf (df/df) mice are deficient in anterior pituitary hormones: growth hormone
(GH), thyroid stimulating hormone (TSH), and prolactin (PRL) due to a spontaneous,
homozygous mutation of prop1df gene. These dwarf mice exhibit characteristics such as delayed
growth and development coupled with delayed aging, increased lifespan, overall increased
insulin sensitivity, as well as resistance to certain diseases and cancers. The mutant mice possess
low blood glucose, low serum insulin, and lower body temperature. Their enhanced longevity
(about 40-60% longer lifespan than normal mice) is associated with their GH deficiency and
disruption in the somatotropic axis (GH/IGF-1 hormonal pathway) as well as increased insulin
sensitivity, which is supported by other mutant mouse models for longevity like Snell dwarfs and
growth hormone receptor knock-out (GHRKO) mice. When young male Ames dwarf mice were
treated with GH replacement therapy, they showed increased body growth to nearly match the
normal mouse phenotype. In conjunction to an increase in physical growth, however, GH
treatment also decreases the longevity and insulin sensitivity that are characteristic of these mice
to levels seen in normal mice. Because of the lack of TSH, they also have undetectable levels of
Thyroxine (T4). While T4 treatment didn’t increase bodyweight of dwarfs to the same extent as
GH treatment, the T4 treated mice retained their enhanced lifespan. Although df/df mice have
enhanced whole-body insulin sensitivity, the male skeletal muscle was previously shown to be
less responsive to insulin than their liver. In our study we analyzed the insulin signaling pathway
in skeletal muscle from female mice after treatment with GH or GH combined with T4. Gene
expression and protein expression were investigated in the skeletal muscle of female Ames dwarf
mice that were treated with GH or GH and T4 therapy. Real Time Polymerase Chain Reaction
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(RT-PCR) was used to analyze the expression of mRNA involved with insulin and GH signaling,
while western blots were used to analyze protein expression. This project found that female
Ames skeletal muscle didn’t respond to GH treatment to the same extent as males, and that GH
and T4 treatment tends to neutralize the effects seen in GH-only treatment.
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INTRODUCTION
The 5.8 kDa peptide hormone, insulin, has gained major attention in recent years and is
practically a household term. It is an anabolic hormone secreted by β-cells of the pancreas and
signals insulin sensitive tissues, such as the liver, adipose tissue, and skeletal muscle, to uptake
glucose from plasma. Insulin and its signaling components are important for regulating glucose
metabolism. Insulin is a pioneering protein, as it was the first protein to be sequenced (earning
Frederick Sanger the Nobel Prize), the first peptide drug, the first recombinant drug, and the first
hormone gene cloned [1-3]. It is the most commonly prescribed peptide drug, and used to help
with glycemic control in patients with Diabetes Mellitus [4].
The metabolic disorder, Diabetes Mellitus (DM), is reaching epidemic proportions in
developed nations like the United States of America, growing even in children and adolescent
populations [5-7]. In the US, more than 8% of the population or 25.8 million people have
diabetes as of 2011 [8]. Furthermore, the estimated total economic cost of diabetes was
approximately $218 billion in 2007 [8]. Type 2 DM, formerly known as Non Insulin Dependent
Diabetes Mellitus, is usually associated with co-morbidities, such as obesity or metabolic
syndrome, and is the leading cause of kidney failure [7, 8]. Ninety percent of diabetics are
afflicted with the Type 2 form of the disease, which is characterized by elevated blood glucose
(hyperglycemia) and elevated blood lipids (hyperlipidemia) in the fasted and fed state, temporary
hypersecretion of insulin, and higher insulin resistance [9, 10]. Abnormal glucose metabolism,
including hyperglycemia and glucose intolerance, is associated with increased cancer risk [11].
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Incidence of insulin resistance and glucose intolerance generally increases in accordance
with age, beginning in the third or fourth decade, as approximately 27% of people over 65 years
old are diabetic [8, 12]. Insulin signaling has been shown to have important effects on longevity
and aging, as some selective alterations in this pathway can lead to increases in lifespan in
several organisms, such as mice [13]. In support of this, interventions such as 30% calorie
restriction (CR) has been shown to improve insulin sensitivity, delay aging, and prolong lifespan
in laboratory rodents while reducing growth, body weight, and thyroid hormones [14, 15]. CR
also delays onset of age associated diseases, including cancer [15].
Ames dwarf mice (df/df), have a homozygous recessive prophet of pit-1 (prop1df)
mutation, which leads to an underdeveloped adenohypophysis (anterior pituitary). This impaired
development of the pituitary gland leads to undetectable levels of circulating growth hormone
(GH), prolactin (PRL), and thyroid stimulating hormone (TSH); this in turn causes suppression
of circulating insulin-like growth factor 1 (IGF-1) and L-thyroxine (T4), as well as plasma insulin
and glucose [16, 17]. Meanwhile, Ames dwarf mice exhibit an increased resistance to some
cancers and delayed development of malignant neoplasms [18, 19]. The GH and IGF-1
deficiencies in df/df mice may be responsible for the delayed development of fatal neoplastic
lesions or tumors [18]. The df/df mouse is used as a model for research of slowed aging and
extended longevity (live approximately 50% longer than normal littermates) while displaying
increased insulin sensitivity in the liver yet reduced insulin response in skeletal muscle at the
same signaling steps [20, 21]. “This reduced insulin response in skeletal muscle may be
important for control of glucose homeostasis in these animals and have implications in their
extended longevity [21].” In addition, the increased life extension of Ames dwarf feature similar
2

characteristics to normal mice in a CR regimen (like increased insulin sensitivity); however, CR
is not an Ames emulation [18, 22]. Interestingly, when CR is utilized in conjunction with Ames
dwarf mice, there is further extension of lifespan in the already long lived mutants [14].
Overall, Ames dwarf mice have undetectable GH levels and increased responsiveness in
terms of insulin signaling, which has been associated with their longevity [23]. GH is an
important modulator of insulin sensitivity, as excess concentrations of GH are associated with
hyperinsulinemia, a decrease in insulin receptor (IR) levels, and a decrease in the activity of IR
kinase [24-26]. GH doesn’t directly interact with the insulin receptor (IR), but its diabetogenic
effects possibly result from signaling cross-talk between GH and insulin pathways as several
post-receptor events are shared between the two. The membrane associated insulin receptor
substrate (IRS) proteins of the insulin pathway seems to be a focal point where the signaling
pathways can intersect (see Supplement 1 in Appendix). Both use the PI3-K / Akt pathway as
part of their downstream signaling cascades. Furthermore, GH has been described to have acute
effects on carbohydrate metabolism that are insulin-like, including translocation of GLUT4 to
the plasma membrane, yet anti-insulin chronic effects [24]. Insulin sensitive tissues include the
liver, adipose tissue, and skeletal muscle tissue. Skeletal muscle tissue is the largest insulinsensitive organ in the body, so insulin resistance in this striated tissue will have a major impact
on whole-body glucose homeostasis [27]. There are a few suggestions on how GH affects insulin
signaling in skeletal muscle. As stated by Dr. Dominici: “In skeletal muscle, GH-induced insulin
resistance might involve an increase in the amount of the p85 subunit of PI3K that plays a
negative role in insulin signaling. GH also reduces insulin sensitivity by enhancing events that
negatively modulate insulin signaling such as stimulation of serine phosphorylation of IRS-1,
3

which prevents its recruitment to the IR [24].” In other words, GH signaling may negatively
regulate the insulin signaling cascade by affecting the quantity or activation of downstream
proteins shared between the two.
Because they also lack the anterior pituitary hormone, TSH, Ames dwarf mice are also
severely deficient in thyroid hormones. Thyroid hormones regulate development, thermogenesis,
and metabolic homeostasis of most cells. After stimulation by TSH, the thyroid gland mostly
secretes thyroxine (T4) into the bloodstream to circulate until it reaches target tissues. At these
target tissues, T4 is converted into the more potent triiodothyronine (T3) to exert actions on
regulating energy metabolism. The scarcity of T4 in Ames dwarf mice leads to a lower body
temperature compared to normal mice, which may tie in to the rate of living theory of aging
since body temperature can be indicative of metabolic rate; this theory suggests that an
organism’s lifespan is inversely correlated with its metabolic rate [16, 28]. In a previous study
using the same animal groups as our project, combination treatment of GH and T4 in Ames
dwarf mice increased their bodyweight to nearly match normal control mice at 84% [29]. As
demonstrated in another study, early life treatment of just T4 slightly increases bodyweight in
female dwarfs and doesn’t reduce longevity, unlike early life GH treatment [30]. We
hypothesized that the combination of GH and T4 therapy to young, developing Ames dwarf mice
will alter genetic expression to reduce the mutants’ insulin sensitivity to match normal mice
more closely than GH treatment alone.
In this project, we examined the effects of GH treatment and GH + T4 combination
treatment on insulin signaling in female Ames dwarf mouse skeletal muscle tissue. This study
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was based on previous experiments [26, 29]. It has been reported that GH treatment in Ames
dwarf mice decreases insulin sensitivity [26]. This study was performed to determine if the
alterations in whole body insulin sensitivity after GH and T4 treatment in Ames dwarf mice are
due to genetic and/or protein changes of the insulin signaling pathway in skeletal muscle by
hormonal therapy. We can help determine which components of the insulin signaling pathway
are affected by growth hormone. This study is significant, as it will help elucidate the effects that
GH and T4 may play on insulin signaling and therefore improve understanding of insulin
resistance, which is a characteristic of aging as well as major pathologies such as type 2 diabetes
and metabolic syndrome.
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MATERIALS AND METHODS
Animals
In a breeding colony, normal heterozygous (N/df) females were mated with homozygous
(df/df) mutant males to produce the Ames Dwarf and N/df mice. The mice were housed under
light- and temperature- controlled conditions, with a 12-hour light and 12-hour dark cycle and
the temperature maintained at 20-23⁰C. Nutritionally balanced food was provided ad libitum
(Rodent Laboratory Chow 5001: 23.4% protein, 4.5% fat, 5.8% crude fiber; LabDiet PMI Feeds,
Inc., St Louis, MO). The animal study was completed at Southern Illinois University in
Springfield Illinois following SIU Laboratory Animal Care Committee approval. [26, 29]
This experiment analyzed four different groups of female mice: a normal control group of
N/df treated with 0.9% saline, a mutant control group of Ames Dwarfs treated with 0.9% saline,
Ames Dwarfs treated with porcine-GH, and Ames Dwarfs treated with GH and T4. There are 810 animals belonging to each group. GH treatment started at 2 weeks of age and lasted for 6
weeks, ending when the mice were 8 weeks of age. After this 6 week treatment period, the mice
were fasted overnight for insulin stimulation and then sacrificed by cervical dislocation 12 hours
later. Half of the animals in each group (4-5 mice per group) were injected with porcine insulin
(Sigma, St. Louis, MO) at dose of 10IU/kg bodyweight via the inferior vena cava before being
sacrificed. Fasting blood glucose levels were also measured before sacrifice from blood collected
through the tail vain using the OneTouch Ultra glucose meter (Life Scan, Inc. Milpitas, CA). The
other half was treated with saline instead of insulin before cervical dislocation as a control.
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Samples tissues were harvested and frozen on dry ice immediately to be stored at -80⁰C until
analysis.

Treatment
For preparation of the GH, porcine-GH (Alpharma, Victoria, Australia) was dissolved in
0.1M NaHCO3 for stability, then 0.9% saline was added to make a single injection concentration
of 21μg/50μL for the average animal bodyweight of 7g (3μg/g of bodyweight). GH injections
were performed twice a day on weekdays with each injection administering half the daily dose
(~3μg/g); the first injection was ~9am and the second was ~4pm (~6μg/g/day total GH
treatment). On weekends, only one injection was performed with the full daily dosage
(~6μg/g/day).
For the preparation of the T4, L-thyroxine (Sigma, St Louis, MO) was placed in a 0.9%
saline solution with a pH of 7.8. It was administered to the mice three times per week (Monday,
Wednesday, and Friday) via subcutaneous injections (0.1μg/g body weight; 0.7 μg/50μL dose).
Preliminary experiments, based on previous studies, in the Ames dwarf colony were used
to determine the dosage for treatment [26].
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Methodology
Insulin Tolerance Test (ITT) was performed after 5 weeks of GH treatment to separate set
of female mice that underwent the same duration and dosage of treatment. The groups of mice
also included wild-type normal controls, untreated Ames dwarf controls, and GH treated Ames
dwarfs. For the ITT procedure, food was removed on the morning of the test, 2 hours before the
first glucose measurement. A Glucometer ONE Touch Ultra (Life Scan, Inc.) was used to
measure basal glucose in blood from the tip of the tail. The mice were then injected with
0.75IU/kg of bodyweight of porcine insulin (Sigma, St. Louis, MO); blood glucose was
measured by Glucometer 15, 30, and 60 minutes after insulin stimulation [26]. Three days after
ITT, Glucose Tolerance Test (GTT) was performed. Mice were fasted overnight and in the
following morning after initial blood glucose measurement, animals were injected with 2 grams
per kilogram of bodyweight of glucose solution intraperitoneally. Following the injection, blood
glucose was measured at: 15 min, 30 min, 60 min, and 120 min using the Glucometer, same as in
the ITT procedure [26].
Gene and protein analysis was performed directly from the skeletal muscle tissue samples
harvested from the animals stated above. Real Time Polymerase Chain Reaction (RT-PCR) was
used to analyze expression of the following genes: IR, IRS1, IGF-1, GHR, GLUT4, Akt2, PGC1α, PI3K, PPAR-γ, STAT1, STAT5a, and STAT5b. The Western Blot technique was used to
analyze the expression of the proteins Akt and p-Akt [Ser473].
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Statistics
Microsoft Excel and GraphPad Prism5 software was used to calculate the raw data. RTPCR calculation equation can be found in the Gene Expression Analysis section. Statistics were
calculated on Prism5 via two-tailed P values for unpaired t tests. Differences between groups that
generated a p value < 0.05 were considered statistically significant.

Gene Expression Analysis:
First, mRNA was extracted from the sample tissue using the Qiagen miRNeasy Mini Kit.
Approximately 75mg of sample tissue was cut from each skeletal muscle sample, and then
placed in a 1.5mL safe-lock tube with 1mm Zirconium oxide beads and 700μL of QIAzol Lysis
Reagent. Samples were homogenized in a bullet blender at speed 10 for 2 minute periods, and
then cooled on wet ice for 2 minutes. This blending and cooling was repeated 3 times per sample
or until well homogenized. From here, the Quick-start Protocol included in the kit was followed
as outlined by Qiagen, including the DNase digest steps. The result of using the kit was
approximately 40μL of purified mRNA in nuclease free water (NF H2O). RNA concentration
was approximated using agarose gel electrophoresis as well as Nanodrop procedure with the
Epoch Gen5 Plate Reader (see appendix for procedure details).
Following mRNA extraction was cDNA synthesis with the Bio-Rad kit. After the mixture
of master-mix (5x iScript reaction mix and iScript reverse transcriptase) with mRNA templates
(derived from the tissue samples) in PCR tubes according to protocol, the reaction mix samples
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were placed into a Bio-Rad MJ Mini Personal Thermal Cycler. The machine conditions were set
at 25⁰C for 5 min, at 42⁰C for 30 min, at 85⁰C for 5 min, then hold at 4⁰C when finished. This
lead to cDNA samples in 20μL of NF H2O; 40-60μL of NF H2O was added to each sample to
dilute them and narrow the range of B2M cycle threshold (CT) values with RT-PCR (see below).
The cDNA samples were stored at 4⁰C until analysis (if there was a long period of time between
cDNA synthesis and RT-PCR analysis, the cDNA samples were frozen at -20⁰C).
This cDNA was used for RT-PCR analysis. 2μL of cDNA was used per sample in a 96
well PCR plate. The forward and reverse primers for the gene of interest were prepared with
SYBR Green and NF H2O in a master mix according to Applied Biosystems protocol, then added
to the 96 well plate containing the cDNA samples for a total of 20μL per well. For PCR protocol
and table of primers used, see appendix.
To normalize the RT-PCR data, Beta 2 Microglobulin (B2M) was selected as the
housekeeping gene. When CT values had a maximum range of 3 between all samples, gene
analysis began. The following equation was used for calculating relative expression: 2A-B/2C-D (A
= CT number of the gene of interest in the first control sample, B = CT number of the gene of
interest in each sample, C = CT number of B2M in the first control sample, D = CT number of
B2M in each sample). This lead to the first control sample having a relative expression of 1, and
all other samples were calculated in relation to this first sample. The results of the normal (N/df)
group were averaged, and all other results were divided by this average to obtain the fold change
of expression of the genes of interest compared to this control group [29].
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Protein Analysis:
Protein was extracted from the skeletal muscle tissue using Thermo Scientific’s Tissue
Protein Extraction Reagent (TPER) protocol. 100mg tissue was cut from the skeletal muscle
sample and placed in a 1.5mL safe-lock microcentrifuge tube with 1mm Zirconium oxide beads
and 300μL of TPER. Samples were well homogenized using the bullet blender at speed 10 for 2
minute periods, then cooled on wet ice for 2 minutes between each run. This blending and
cooling process was repeated 3 to 4 times per sample until well homogenized. The samples were
then centrifuged at 13,000 rpm for 10 minutes at 4⁰C to pellet the tissue/cellular debris. The
supernatant was collected via micropipette, carefully avoiding any intramuscular fat that settled
on the surface of the solution. The samples were frozen at -80C until ready for analysis.
The Pierce BCA Protein Assay Kit (Thermo Scientific) was used according to the
microplate procedure to determine total protein concentration in each sample. The BCA assay is
a copper (II) reduction colorimetric protein assay; it is similar to the Bradford Assay. 1:10
dilution was used; 2.4μL sample protein was mixed with 21.6μL of TPER for a total of 24μL per
BCA sample. 10μL of each diluted BCA protein sample was pipetted per well into a 96 well cellculture plate in duplicates; bovine serum albumin (BSA) standards were added to the plate in
duplicates as well. 200μL of BCA working reagent was added to each well and the plate was
incubated at 37⁰C for 30 min. After incubation, the plate was cooled to room temp and then
absorbance was analyzed in the Epoch Gen5 Plate reader at 562nm. The protein concentrations
were automatically extrapolated from a standard curve generated from set concentrations of
BSA. With this protein concentration data, Microsoft Excel was used to calculate the volume of
11

each protein sample to be used in order to load 60μg of protein within a 14μL volume per well.
4X sample buffer (with β-mercaptoethanol in a 19:1 ratio) was added to each protein sample in a
1:3 ratio (sample buffer : sample protein + TPER).
SDS-PAGE was performed using 26 well 10% Criterion TGX Precast Gels (stored at 4⁰C
until use). The electrophoresis and western transfer procedure specifications are included in the
appendix. Pierce Reversible Protein Stain Kit for PVDF membranes (Thermo Scientific) was
used as a loading control. This allows one to easily visualize all nonspecific protein bands within
the membrane. Normally β-actin or β-tubulin housekeeping proteins would be used as loading
controls for normalization and monitor for equal protein loading. However, probably due to the
complication of smaller cell size for Ames dwarf mice, this lead to an inconsistent comparison
between dwarf and normal groups even when the same amount of protein was pipetted in each
well. In any case, these housekeeping proteins were not expressed uniformly, leading to potential
normalization issues. These issues were overcome by staining all proteins indiscriminately and
using this data to monitor relative protein loading.
Membranes were imaged with the Li-Cor Odyssey Infrared Imager and ImageStudio
Version 2.1 software. Median background noise was subtracted from signal value to produce the
true band intensity values. These values were used in GraphPad Prism 5 software to generate
comparison graphs and for statistical analysis. Specific details and information regarding the
antibodies used can be found in the appendix.
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RESULTS
Bodyweight
Ames dwarf mice are significantly smaller than normal (wild-type) control mice (p <
0.0001). However, after either GH or GH and T4 treatment, the dwarf mice grow significantly
larger and match the bodyweight of normal mice (p < 0.0001) (Figure 1).

Figure 1 – Bodyweight comparison of female wild-type (WT) mice, untreated Ames dwarf mice (df/df), GH treated
Ames dwarf mice (df/df GH), and Ames dwarf mice treated with both GH and T4 (df/df GH + T4). WT, n = 10;
df/df, n = 10; df/df GH, n = 10; and df/df GH + T4, n = 8. Groups that do not share a superscript are significantly
different (p < 0.05).
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Fasting Blood Glucose
GH treatment to female Ames dwarf mice increased fasting blood glucose levels
compared to normal mice (p = 0.0163). However, GH and T4 treatment showed no significant
increase above wild-type mouse fasting blood glucose levels, instead matching untreated Ames
dwarfs (Figure 2).

Figure 2 – Fasting blood glucose measurements in wild-type mice (WT), Ames dwarf mice (df/df), Ames dwarf
mice treated with GH (df/df GH), and Ames dwarf mice treated with both GH and T4 (df/df GH + T4). WT, n = 10;
df/df, n = 10; df/df GH, n = 10; and df/df GH + T4, n = 8. Groups that do not share a superscript are significantly
different (p < 0.05).
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Insulin Tolerance Test and Glucose Tolerance Test
ITT and GTT were performed in a separate study using the same mouse models, the same
treatment regimen, and the same dosages. Female Ames dwarf mice were treated with GH for 6
weeks, starting at 2 weeks of age, using the same dose as described above; then their insulin
tolerance and glucose tolerance were compared to untreated wild-type mice and untreated
dwarfs.
For both the ITT and GTT, GH treatment did not demonstrate a significant decrease in
either whole-body insulin sensitivity or glucose tolerance when compared to untreated dwarfs,
who are characterized by improved ITT and GTT (Figures 3 and 4).
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Figure 3 – Insulin Tolerance Test of GH treated female Ames dwarf mice compared to age and sex-matched normal
and dwarf controls. X-axis indicates Time in minutes; Y-axis indicates percent of Blood Glucose measurements
compared to baseline.
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Figure 4 – Glucose Tolerance Test (GTT) of GH treated female Ames dwarf mice compared to age and sexmatched normal and dwarf controls. X-axis indicates Time in minutes; Y-axis indicates Blood Glucose in mg/dl.

mRNA Expression
Insulin receptor mRNA levels significantly decreased in mice treated with both GH and
T4 (GH+T4) when compared to normal (p=0.0064), saline treated dwarfs (p=0.0255), and GH
treated df/df mice (p=0.0097) (Figure 5-A). While normal and saline treated dwarfs had the same
levels of IRS-1 mRNA, GH treated dwarfs showed a significant increase compared to both
groups (WT vs. df/df GH p=0.0150; df/df vs. df/df GH p=0.0179). However, GH + T4 treated
dwarfs showed no significant differences between any of the other groups (Figure 5-B). While
saline treated dwarfs and GH treated dwarfs showed no difference in PI3-K mRNA levels with
any groups, GH+T4 treated mice show about half the expression compared to normal mice
17

(p=0.0332) (Figure 5-C). Evident in Figure 5-D, normal mice and GH treated mice share the
same relative expression of Akt2 mRNA, yet Akt2 mRNA levels decreased in GH+T4 treated
dwarfs compared to both groups (WT vs. df/df GH+T4 p=0.0118; df/df GH vs. df/df GH+T4
p=0.024). Saline treated dwarfs have numerically lower levels of expression compared to normal
and GH treated dwarfs, but show no statistically significant differences between any groups.

A.)

B.)

C.)

D.)

Figure 5. Relative gene expression of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), PI3-K, and Akt2
mRNA in female Ames dwarf (df/df) mice after growth hormone (GH) and thyroxine (T4) treatment. X-axis
represents different animal treatment groups; Y-axis represents relative mRNA expression of the gene of interest.
(A) Skeletal Muscle IR mRNA in wild-type (WT), n = 10; df/df, n = 10; df/df GH, n = 10; and df/df GH+T4, n = 8.
(B) Skeletal Muscle IRS-1 mRNA in WT, n = 10; df/df, n = 10; df/df GH, n = 10; and df/df GH+T4, n = 8. (C)
Skeletal Muscle PI3-K mRNA in WT, n = 10; df/df, n = 10; df/df GH, n = 10; and df/df GH+T4, n = 8. (D) Skeletal
Muscle Akt2 mRNA in WT, n = 10; df/df, n = 10; df/df GH, n = 10; and df/df GH+T4, n = 8. Groups that do not
share a superscript are different with statistical significance (p < 0.05).
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PPAR-γ mRNA for normal and GH treated dwarfs were at equal levels, yet showed no
statistical differences with any groups. However, GH+T4 treatment in dwarfs elicited a
significant reduction in PPAR-γ expression compared to saline treated dwarfs (p=0.0267) (Figure
6-A). Although normal mice had numerically higher levels PGC-1α mRNA compared to all
other groups, statistics showed no significant differences (Figure 6-B). Growth hormone receptor
(GHR) expression shares a similar expression pattern to Akt2, as demonstrated in Figure 6-C.
Normal and GH treated dwarfs have the same GHR mRNA levels while GH+T4 treatment
suppresses expression to approximately half (p=0.0076 and p=0.0232 respectively). Again,
saline treated dwarfs show no statistically significant differences with any groups. On the other
hand, saline treated dwarfs showed higher expression of IGF-1 mRNA compared to normal mice
(p=0.0073). Treatment of dwarfs with GH brought IGF-1 mRNA to substantially higher levels
than both normal and saline treated dwarf groups (p=0.0005 and p=0.0031 respectively).
However, the addition of T4 treatment in conjunction with GH brought levels back down to
match saline treated dwarfs (WT vs. df/df GH+T4 p=0.0066; df/df GH vs. df/df GH+T4
p=0.0231) (Figure 6-D).
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A.)

B.)

C.)

D.)

Figure 6 - Relative gene expression of Peroxisome Proliferator Activated Receptor gamma (PPAR-γ), PGC-1α,
growth hormone receptor (GHR), and IGF-1 mRNA in female Ames dwarf (df/df) mice after growth hormone (GH)
and thyroxine (T4) treatment. X-axis represents different animal treatment groups; Y-axis represents relative mRNA
expression of the gene of interest. (A) Skeletal Muscle PPAR-γ mRNA in wild-type (WT), n = 10; df/df, n = 10;
df/df GH, n = 10; and df/df GH+T4, n = 8. (B) Skeletal Muscle PGC-1α mRNA in WT, n = 10; df/df, n = 10; df/df
GH, n = 10; and df/df GH+T4, n = 8. (C) Skeletal Muscle GHR mRNA in WT, n = 10; df/df, n = 10; df/df GH, n =
10; and df/df GH+T4, n = 8. (D) Skeletal Muscle IGF-1 mRNA in WT, n = 10; df/df, n = 10; df/df GH, n = 10; and
df/df GH+T4, n = 8. Groups that do not share a superscript are different with statistical significance (p < 0.05).

STAT-5a gene expression showed no differences between any groups (Figure 7-A).
However, GH treatment significantly suppressed STAT-5b gene expression in dwarf mice
(p=0.0376) and GH and T4 treatment suppressed expression even further (p=0.0188) (Figure 7B). STAT-1 mRNA expression followed the same trends as Akt2 and GHR. Normal and GH
treated dwarfs have the same STAT-1 gene expression, while GH+T4 treatment of dwarfs were
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significantly less than both (p=0.0098 and p=0.0054 respectively); saline treated dwarfs showed
no major differences with any groups (Figure 7-C). Saline treated dwarf mice had a lower
mRNA expression of GLUT4 compared to normal mice (p=0.0093); GH treatment of dwarfs
corrected the GLUT4 mRNA expression back to levels of normal mice, which is higher than the
saline treated dwarfs (p=0.0143). However, GH and T4 treatment dropped GLUT4 gene
expression back down to levels lower than normal, dwarf, and GH treated dwarf mice (p=0.0044,
p=0.0432, p=0.0016 respectively) (Figure 7-D).

A.)

B.)

C.)

D.)

Figure 7 - Relative gene expression of STAT-5a, STAT-5b, STAT-1, and GLUT4 mRNA in female Ames dwarf
(df/df) mice after growth hormone (GH) and thyroxine (T4) treatment. X-axis represents different animal treatment
groups; Y-axis represents relative mRNA expression of the gene of interest. (A) Skeletal Muscle STAT-5a mRNA
in wild-type (WT), n = 9; df/df, n = 10; df/df GH, n = 10; and df/df GH+T4, n = 8. (B) Skeletal Muscle STAT-5b
mRNA in WT, n = 10; df/df, n = 10; df/df GH, n = 10; and df/df GH+T4, n = 8. (C) Skeletal Muscle STAT-1
mRNA in WT, n = 10; df/df, n = 10; df/df GH, n = 10; and df/df GH+T4, n = 8. (D) Skeletal Muscle GLUT4 mRNA
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in WT, n = 10; df/df, n = 10; df/df GH, n = 10; and df/df GH+T4, n = 8. Groups that do not share a superscript are
different with statistical significance (p < 0.05).

Protein Expression
The protein analysis providing successful Western Blot data were total Akt (Figure 8)
and p-Akt Ser473 (Figure 9). Preliminary Western Blot runs of p-Akt [s473] showed no signal
and no expression levels in saline stimulated mice. Because of this, only insulin stimulated mice
were included in the following blot to increase the number of mice per group. During statistical
analysis of the p-Akt [s473] blot, a couple of the outlier sample values were omitted from the
data set; preliminary western blot data indicated an incomplete insulin stimulation of these
omitted mice, providing artificially low phosphorylation levels and skewing the data. By
omitting this skewed data, the standard error decreased. As seen in Figure 9, untreated and GH
treated dwarf mice had lowered total Akt expression compared to normal mice (p < 0.01).
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WT

Df/df

Df/df GH

Df/df GH + T4

Akt
Control

Figure 8 – Expression of total Akt protein in the skeletal muscle of female wild-type mice (WT), Ames dwarf mice
(df/df), Ames dwarf mice with GH treatment (df/df GH), and Ames dwarf mice with GH and T4 treatment (df/df
GH + T4). WT, n = 6; df/df, n = 6; df/df GH, n = 6; df/df GH + T4, n = 6. Groups that do not share a superscript are
significantly different (p < 0.05).
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Df/df

WT
pAkt [s473]

Df/df GH
X

X

Df/df GH + T4
X

Control

Figure 9 – Expression of Akt protein phosphorylated at serine residue 473 in the skeletal muscle of female wildtype mice (WT), Ames dwarf mice (df/df), Ames dwarf mice with GH treatment (df/df GH), and Ames dwarf mice
with GH and T4 treatment (df/df GH + T4). WT, n = 4; df/df, n = 3; df/df GH, n = 4; df/df GH + T4, n = 3. “X”
indicates a sample omitted due to unusually low values (probably attributed to incomplete insulin stimulation).
Groups that do not share a superscript are significantly different (p < 0.05).

24

DISCUSSION
Due to underdeveloped anterior pituitary glands, Ames dwarf mice are lacking the
hormones: growth hormone (GH), thyroid stimulating hormone (TSH), and prolactin. These
mice feature several noteworthy characteristics compared to age matched normal control mice,
including: smaller size and bodyweight, delayed development and aging with increased lifespan,
and enhanced insulin sensitivity and glucose tolerance. Other long-living mutant mouse models,
namely the Snell dwarf mouse and growth hormone receptor knock-out (GHRKO) mouse, also
share a disruption in the GH / IGF-1 pathway. This suggests that interfering with GH / IGF-1
signaling and increased insulin sensitivity with reduced insulin levels promotes a lifespan
enhancing effect [31-34].
In previous studies, reintroducing GH to male Ames dwarf mice via hormone
replacement therapy caused the mutants to nearly match the phenotype of normal controls. GH
treatment to young mice increases size and bodyweight significantly. Compared to untreated
dwarfs, the male dwarf mice on GH therapy showed increased levels of serum glucose, insulin,
and IGF-1 along with a decrease in insulin sensitivity and lifespan [26]. GH and T4 combination
treatment has also shown significant increases in size and bodyweight of male Ames dwarfs [29].
On the other hand, Ames dwarf mice treated with only T4 showed a bodyweight increase without
any significant effects on lifespan [30]. Because of this, GH was initially of greater interest in
this study.
In our experiment involving female Ames dwarf mice, both GH treatment and GH + T4
combination treatment significantly increased the dwarf mouse bodyweight to match wild-type
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controls. However, combining GH and T4 treatment increased bodyweight to the same extent as
GH treatment alone. In other words, adding T4 treatment to the HRT regimen didn’t increase
bodyweight any greater than GH treatment alone. Also in our study, both the untreated and GH +
T4 treated female dwarf mice had no significant difference in fasting blood glucose compared to
normal mice. Yet, GH treatment increased dwarf fasting blood glucose relative to normal mice,
demonstrating a diabetogenic effect of GH treatment. It seems that thyroxine injections in
conjunction with GH treatment helped prevent this elevation in blood glucose. Surprisingly, the
untreated Ames dwarf mice had the same blood glucose levels as normal mice instead of the
expected lower blood glucose levels.
ITT can be used to measure an animal’s whole body insulin sensitivity. After insulin
injection, more insulin responsive animals will show a more rapid and pronounced drop in blood
glucose levels from baseline. This demonstrates that the same dose of injected insulin produces a
greater effect on the body’s blood glucose levels, implying better whole-body insulin sensitivity.
GTT is used to measure an animal’s glucose tolerance. Injection of glucose solution imitates the
post-prandial elevation in blood glucose. Animals with greater glucose tolerance will exhibit a
more rapid decline in blood glucose to basal levels. This demonstrates the animals’ ability to
regulate blood glucose levels by detecting and responding to changes in blood glucose, secreting
adequate insulin, and responding to the insulin.
In previous experiments with males, GH treatment decreased glucose tolerance and
insulin tolerance of Ames dwarf mice, bringing them to levels observed in wild-type mice [23,
26]. Interestingly, regardless of complete normalization of bodyweight, the same dosage of GH
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treatment for the same duration didn’t significantly affect insulin sensitivity and glucose
tolerance in female Ames dwarf mice, as shown by ITT and GTT (Figure 3 and Figure 4). This
difference in response to GH treatment may suggest that twice-daily GH injections more closely
emulate the natural pulsatile GH secretion pattern of males. This offers a potential explanation
for the lack of significant effects on insulin and glucose metabolism in female Ames dwarf mice
after GH treatment.
As shown by Dr. Dominici and colleagues, the insulin sensitivity responses of Ames
dwarf mice may be tissue specific. According to that study, Ames dwarf skeletal muscle shows a
decreased response to large dose insulin stimulation (10Ug/kg bodyweight), which is opposite of
their findings with liver. They demonstrated with western blots that when compared to normal
mice, Ames dwarf mice skeletal muscle tissue had decreased insulin response or protein
phosphorylation of IR, IRS-1, PI3-K, and Akt. In this same study, there were no differences in
amounts of IR and Akt protein yet decreased amount of IRS-1, and PI3-K. It was suggested that
the decreased insulin sensitivity of the skeletal muscle is a protective mechanism against severe
hypoglycemia [21]. This makes sense, considering that skeletal muscle utilizes a large proportion
of available blood glucose, having highly insulin sensitive skeletal muscle may deplete the blood
glucose to dangerously low levels. In our own analysis, IR, IRS-1, PI3-K, and Akt mRNA also
indicated no difference between dwarf and normal mice at the gene expression level in skeletal
muscle. However, in the study of male Ames mouse liver after GH and T4 treatment, they found
decreased dwarf mRNA to match normal mouse levels for: IR, IRS-1, PPAR-γ, and PGC-1α. At
the same time, IGF-1 gene expression of dwarf mice increased to match normal mice due to the
dual hormone treatment [29].
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In accordance with the Dominici study in 2003, this project showed an increase in IGF-1
and a decrease in GLUT4 gene expression for untreated dwarf skeletal muscle, correlating to a
decrease in insulin signaling in skeletal muscle. However, in contrast to the findings in the liver
of GH and T4 treated Ames dwarf mice [29], our study showed no effects on gene expression in
skeletal muscle to correlate with the ITT and GTT data. This important finding shows that
females respond to GH treatment similarly to males for body growth, however, treatment of
these GH deficient mice doesn’t affect insulin signaling in the skeletal muscle of these long
living rodents.
Surprisingly, most of the significant differences in mRNA levels were demonstrated by
the GH + T4 treated dwarf mouse group. When referring to Figures 5, 6, and 7 for Akt2, PPARγ, GHR, IGF-1, STAT-1, and GLUT4 mRNA, it can be observed that the addition of T4
treatment opposes the actions of GH treatment alone.
On the other hand, some of the data related to an increase of insulin sensitivity. For
example, the GH treatment alone increased dwarf IRS-1 and GLUT4 expression levels. GH and
T4 combination treatment featured lower gene expression for GH signaling by having decreased
GHR, IGF-1, STAT-1, and STAT-5b levels compared dwarf mice treated with only GH.
In terms of protein analysis, the results for total Akt differ than previously shown. The
data in this study (Figure 8) shows dwarf mice having less total Akt than normal mice and this is
only corrected with combining T4 with GH treatment. However, a previous study shows female
Ames dwarf mice having the same levels of total Akt as normal mice, the only difference found
in Akt phosphorylation or activation [21]. Furthermore, while GH treatment suppresses Akt
28

phosphorylation at serine 473 in dwarf skeletal muscle, GH + T4 treatment reverses this change
by increasing activation to normal mouse levels. This shows an opposite trend in the liver, where
GH treatment of dwarf mice increased ser473 phosphorylation of Akt above normal and dwarf
controls [26]. In summary, GH treatment alone didn’t increase Akt expression or activation in
dwarf skeletal muscle, but GH + T4 treatment did cause increases. Once again, only when T4
was used in conjunction with GH therapy did we find significant changes.
One very large possible confounder for the differences in expression is the fact that we’re
comparing our female mouse tissue samples with some data from males. In males, GH is present
at low basal levels; every few hours they have pulsatile secretion of high amounts of GH and
then return to basal levels. Females’ basal level of GH is higher in comparison, yet they have
pulses smaller in amplitude with greater frequency. Based on these physiological differences in
regulation of GH, the twice daily GH treatment regimen for the dwarf mice more closely
matches the natural GH secretion patterns of males than females. In addition, this is only half the
story with gene expression; changes in the mRNA levels of genes don’t always correlate to
changes in translation and protein expression. Further experiments and studies must evaluate the
levels and activation/deactivation of different signaling proteins to determine what steps of the
pathway are being regulated by these hormones in skeletal muscle.
In conclusion, this study found that GH therapy didn’t have major effects on insulin
signaling in skeletal muscle of female Ames dwarf mice. However, combining T4 treatment with
GH therapy suppressed mRNA expression for several genes compared to GH injections alone.
T4 seemed to oppose growth hormone’s changes in expression of some genes, especially GLUT4
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and IGF-1. When looking at the GH + T4 treatment group, thyroxine appeared to be negatively
regulating the gene expression of players in GH signaling in skeletal muscle, including the GHR
gene. We can note the correlating decrease in IGF-1 gene expression with the addition of T4 to
the hormone replacement therapy. We suggest that T4 may be suppressing the gene expression
of the GH signaling pathway, therefore counteracting some of the effects of GH replacement in
the GH + T4 group. By testing the effects of GH and T4 replacement therapy on skeletal muscle
tissue’s insulin signaling pathway of anterior pituitary hormone deficient mice, we can help
elucidate the role that GH plays in whole body insulin sensitivity, as well as some effects of
combining T4 with GH therapy. This in turn may contribute to better understanding of the
interactions between these hormones and support development of new, safe ways to increase
insulin sensitivity in Type 2 Diabetes patients and the elderly, promoting better health and
quality of life for the future.
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APPENDIX
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Basic GH/Insulin Pathway Investigated

Supplement 1 - Simplified flow chart of the Growth Hormone (GH) and Insulin Signaling pathway, demonstrating
most of the proteins investigated in this study. Adapted from Dominici et al., 2005 [24].
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Agarose Gel Electrophoresis
Mixed 260mL TAE (1x) + 6.25g agarose powder in beaker and boiled in microwave.
Added 25μL SYBR Gold and mixed well before pouring into casting tray with comb. Gel cooled
to room temperature and solidified in approximately 30 min. After solidifying, gel was placed
into buffer bath. 5μL of sample was mixed with loading dye on parafilm and then loaded into
wells. Electrophoresis was run for 40 min with the following specs: 120V / 3A / 300W. Gel was
visualized on Kodak Imaging device with Carestream program. Epoch Plate Reader with Gen5
software was also used to quantify RNA concentration using set programming.

Nano-drop Protocol
2μL of RNA sample was placed in each well of the Take 3 plate for the Epoch Gen 5
Plate Reader, along with duplicates of RNase free water for blanks. The absorbance was read at
260nm to determine relative RNA concentration and an absorbance ratio of 260/280 greater than
1.9 indicated sufficient purity.

RT-PCR Protocol
This project made use of the Applied Biosystems 7500 Fast Real-Time PCR System.
Instrument: 7500 Fast (96 wells)
Type of experiment: Quantitation – Comparative CT (ΔΔCT)
Reagents: SYBR Green (Including Melt Curve)
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Speed: Fast (~40 min)
45 cycles
Used Applied Biosystems Protocol except Anneal/Extend Temp was changed to 64⁰C.
Enzyme Activation: 45⁰C for 20 seconds
Denature: 95⁰C for 3 seconds
Anneal/Extend: 64⁰C for 30 seconds

RT-PCR Primers
Ordered from Integrated DNA Technologies and designed by Xu Zhi
Gene
B2M
IR
IRS-1
PI3-K
Akt2
GHR
IGF-1
STAT-1
STAT-5a
PPAR-γ
PGC-1α
GLUT4

Primer
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

Sequence (5' → 3')
AAG TAT ACT CAC GCC ACC CA
CAG GCG TAT GTA TCA GTC TC
GTT CTT TCC TGC GTG CAT TTC CCA
ATC AGG GTG GCC AGT GTG TCT TTA
AGC CCA AAA GCC CAG GAG AAT A
TTC CGA GCC AGT CTC TTC TCT A
TAG CTG CAT TGG AGC TCC TT
TAC GAA CTG TGG GAG CAG AT
GAG GAC CTT CCA TGT AGA CT
CTC AGA TGT GGA AGA GTC AC
AGG TCT CAG GTA TGG ATC TTT GTC A
GCC AAG AGT AGC TGG TGT AGC CT
CTG AGC TGG TGG ATG CTC TT
CAC TCA TCC ACA ATG CCT GT
CGA CCA GTA CAG CCG CTT TT
CGG GAT CTT CTT GGA AGT TAT CCT
ACC ACC TTC AGT GTA AGG AG
AAA GGT CAC CAC CGC TTT AG
GTC AGT ACT GTC GGT TTC AG
CAG ATC AGC AGA CTC TGG GT
TAC GCA GGT CGA ACG AAA CT
TGC TCT TGG TGG AAG CA
ATT GGC ATT CTG GTT GCC CA
GGT TCC GGA TGA TGT AGA GGT A
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SDS-PAGE
Bio-Rad Running buffer (1X TGS) and Transfer buffer (1X TG) were almost always
made fresh before use according to directions listed on the package. 5μL of molecular weight
marker loaded in 1st well followed by 14μL of samples; the final empty well was loaded with
14μL of sample buffer (no protein). While the dye was in the stacking gel, the voltage of the
power unit was set to 80V (for approximately 40 min). When the proteins/dye reached the
resolving gel, the voltage was increased to 100V (for approximately 60 min). Running buffer
(1X TGS) was reused once, or until the current approached 0.7A.

Antibodies
Both the Akt and phospho-Akt s473 primary (1⁰) antibodies were purchased from Cell
Signaling Technology and were sourced from rabbits. Antibodies were added to a 1:1 mixture of
Odyssey Blocking Buffer and PBS-T in a 1:750 ratio and stored at -20⁰C until use. When ready
to be used, they were quickly thawed in a 37⁰C water bath and washed the membrane with gentle
shaking overnight in 4⁰C. When finished, the antibody solutions were refrozen at -20⁰C until reuse. Each lab member prepared their own antibody solutions to prevent cross-contamination.
The secondary (2⁰) antibody was Peroxidase Conjugated Affinity Purified anti-Rabbit
IgG (H&L). It was purchased from Applied Biological Materials Inc. and sourced from goats. It
was prepared as a 1:15,000 dilution by adding 2μL of antibodies to a 30mL solution consisting
of Odyssey Blocking Buffer and PBS-T in a 1:1 ratio (15mL of each). This was stored at 4⁰C
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until use and protected from light by aluminum foil wrapping. When in use, it washed the
membrane with gentle shaking for 1 hour while being protected from light.

Western Transfer and Western Blot
PVDF membrane was first cut to a size that matched the polyacrylamide gel and then
activated for 1 min in methanol (MeOH). Transfer buffer was cooled in 4⁰C prior to use. The wet
western transfer was performed with the PVDF membrane and polyacrylamide gel stacked on
top of each other and both sandwiched between filter paper and sponges. The gel was on the side
of the negative electrode while the membrane was on the side of the positive electrode, ensuring
the electrical current would direct the proteins from the gel to the membrane. The sandwich was
placed in the running tank, submerged in cooled transfer buffer along with ice pack and a
magnetic stirring rod. The transfer was performed at 80V for 45 minutes.
When finished with the transfer, the membrane was rinsed in phosphate buffered saline
(PBS) and then blocked in 5% milk (1.5g dry milk powder in 30mL of PBS) for 1 hour. This step
was succeeded by: a 20-30 min wash with phosphate buffered saline with tween (PBS-T), 1⁰
antibody incubation, another 20-30 min wash with PBS-T, 2⁰ antibody incubation, and then
finished off with a final 20 min PBS-T wash and storage in PBS. The washes in PBS-T were
actually 5 minute washes repeated 4-6 times, totaling 20-30 minutes.

36

REFERENCES
1.

Junod, S. Celebrating a Milestone: FDA's Approval of First Genetically-Engineered
Product. Update Magazine 2007 04/10/2009 Available from:
http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SelectionsFromF
DLIUpdateSeriesonFDAHistory/ucm081964.htm.

2.

Stretton, A.O., The first sequence. Fred Sanger and insulin. Genetics, 2002. 162(2): p.
527-32.

3.

Ullrich, A., et al., Rat insulin genes: construction of plasmids containing the coding
sequences. Science, 1977. 196(4296): p. 1313-9.

4.

Edwards, C.M., M.A. Cohen, and S.R. Bloom, Peptides as drugs. QJM, 1999. 92(1): p. 14.

5.

Bloomgarden, Z.T., Type 2 diabetes in the young: the evolving epidemic. Diabetes Care,
2004. 27(4): p. 998-1010.

6.

Pinhas-Hamiel, O., et al., Increased incidence of non-insulin-dependent diabetes mellitus
among adolescents. J Pediatr, 1996. 128(5 Pt 1): p. 608-15.

7.

Zimmet, P., K.G. Alberti, and J. Shaw, Global and societal implications of the diabetes
epidemic. Nature, 2001. 414(6865): p. 782-7.

8.

Data from the 2011 National Diabetes Fact Sheet. American Diabetes Association 2011;
Available from: http://www.diabetes.org/diabetes-basics/diabetes-statistics/.

9.

Basu, R., et al., Obesity and type 2 diabetes impair insulin-induced suppression of
glycogenolysis as well as gluconeogenesis. Diabetes, 2005. 54(7): p. 1942-8.

10.

Strom, J.L. and L.E. Egede, The impact of social support on outcomes in adult patients
with type 2 diabetes: a systematic review. Curr Diab Rep, 2012. 12(6): p. 769-81.

11.

Stattin, P., et al., Prospective study of hyperglycemia and cancer risk. Diabetes Care,
2007. 30(3): p. 561-7.

12.

DeFronzo, R.A., Glucose intolerance and aging. Diabetes Care, 1981. 4(4): p. 493-501.

13.

Bartke, A., Insulin and aging. Cell Cycle, 2008. 7(21): p. 3338-43.

14.

Bartke, A., et al., Extending the lifespan of long-lived mice. Nature, 2001. 414(6862): p.
412.

37

15.

Weindruch, R. and R.S. Sohal, Seminars in medicine of the Beth Israel Deaconess
Medical Center. Caloric intake and aging. N Engl J Med, 1997. 337(14): p. 986-94.

16.

Bartke, A. and R. Westbrook, Metabolic characteristics of long-lived mice. Front Genet,
2012. 3: p. 288.

17.

Miquet, J.G., et al., Ames dwarf (Prop1(df)/Prop1(df)) mice display increased sensitivity
of the major GH-signaling pathways in liver and skeletal muscle. Growth Horm IGF Res,
2010. 20(2): p. 118-26.

18.

Ikeno, Y., et al., Delayed occurrence of fatal neoplastic diseases in ames dwarf mice:
correlation to extended longevity. J Gerontol A Biol Sci Med Sci, 2003. 58(4): p. 291-6.

19.

Ramsey, M.M., et al., Growth hormone-deficient dwarf animals are resistant to
dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis. Endocrinology,
2002. 143(10): p. 4139-42.

20.

Argentino, D.P., et al., Effects of long-term caloric restriction on glucose homeostasis
and on the first steps of the insulin signaling system in skeletal muscle of normal and
Ames dwarf (Prop1df/Prop1df) mice. Exp Gerontol, 2005. 40(1-2): p. 27-35.

21.

Dominici, F.P., et al., The dwarf mutation decreases high dose insulin responses in
skeletal muscle, the opposite of effects in liver. Mech Ageing Dev, 2003. 124(7): p. 81927.

22.

Mattison, J.A., et al., Studies of aging in ames dwarf mice: Effects of caloric restriction. J
Am Aging Assoc, 2000. 23(1): p. 9-16.

23.

Masternak, M.M., et al., Insulin sensitivity as a key mediator of growth hormone actions
on longevity. J Gerontol A Biol Sci Med Sci, 2009. 64(5): p. 516-21.

24.

Dominici, F.P., et al., Influence of the crosstalk between growth hormone and insulin
signalling on the modulation of insulin sensitivity. Growth Horm IGF Res, 2005. 15(5):
p. 324-36.

25.

Dominici, F.P., et al., Loss of sensitivity to insulin at early events of the insulin signaling
pathway in the liver of growth hormone-transgenic mice. J Endocrinol, 1999. 161(3): p.
383-92.

26.

Masternak, M.M., et al., The effects of growth hormone (GH) treatment on GH and
insulin/IGF-1 signaling in long-lived Ames dwarf mice. J Gerontol A Biol Sci Med Sci,
2010. 65(1): p. 24-30.

38

27.

Zierath, J.R. and H. Wallberg-Henriksson, From receptor to effector: insulin signal
transduction in skeletal muscle from type II diabetic patients. Ann N Y Acad Sci, 2002.
967: p. 120-34.

28.

Hunter, W.S., et al., Low body temperature in long-lived Ames dwarf mice at rest and
during stress. Physiol Behav, 1999. 67(3): p. 433-7.

29.

Louis, A., A. Bartke, and M.M. Masternak, Effects of growth hormone and thyroxine
replacement therapy on insulin signaling in Ames dwarf mice. J Gerontol A Biol Sci Med
Sci, 2010. 65(4): p. 344-52.

30.

Panici, J.A., et al., Early life growth hormone treatment shortens longevity and decreases
cellular stress resistance in long-lived mutant mice. FASEB J, 2010. 24(12): p. 5073-9.

31.

Al-Regaiey, K.A., et al., Long-lived growth hormone receptor knockout mice: interaction
of reduced insulin-like growth factor i/insulin signaling and caloric restriction.
Endocrinology, 2005. 146(2): p. 851-60.

32.

Bartke, A., L.Y. Sun, and V. Longo, Somatotropic signaling: trade-offs between growth,
reproductive development, and longevity. Physiol Rev, 2013. 93(2): p. 571-98.

33.

Chen, Y.F., et al., Longevity and lifespan control in mammals: lessons from the mouse.
Ageing Res Rev, 2010. 9 Suppl 1: p. S28-35.

34.

Liang, H., et al., Genetic mouse models of extended lifespan. Exp Gerontol, 2003. 38(1112): p. 1353-64.

39

